Every treatment that has ever made a difference in cancer care was once a part of a clinical trial. MUSC Hollings Cancer Center is committed to offering the best treatments available today while searching for even better ones for the future. Ask your doctor if a clinical trial is right for you.
STUDY17022 First in Human, Phase 1/1b, Open label, Multicenter Study of Bifunctional EGFR/TGF ß Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients with EGFR Driven Advanced Solid Tumors The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driven tumors. Study Information
STUDY22555 Randomized Phase III Trial of M-Folfirinox +/- Nivolumab vs. Folfox +/- Nivolumab for First Line Treatment of Metastatic HER-2 Negtive Gastroesophageal Addenocarcinoma To determine if overall survival (OS) is improved in patients who received mFOLFIRINOX +/- nivolumab in comparison to FOLFOX +/- nivolumab as first-line chemotherapy for metastatic gastroesophageal adenocarcinoma. To compare other indices of efficacy, including progression-free survival, objective response rates and duration of response between both treatment arms. To evaluate safety and tolerability associated with treatment in each of the treatment arms. To evaluate the proportion of patients receiving second line of therapy in both arms. To evaluate tolerability of the treatment in both arms using PRO-CTCAE Study Information
STUDY23589 A Phase 1 Open Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications To assess the efficacy of ABBV-400 in each solid tumor indication, including advanced or metastatic HCC, BTC, PDAC, ESCC, TNBC, HR+/HER2- BC and HNSCC. To characterize the safety and tolerability of ABBV-400 as monotherapy in advanced or metastatic HCC, BTC, PDAC, ESCC, TNBC, HR+/HER2- BC, and HNSCC. Study Information
STUDY24164 A Phase 3, Multicenter, Open-label, Randomized Study to Compare the Efficacy and Safety of MK-2870 Versus Treatment of Physicians Choice in 3L+ Advanced/Metastatic Gastroesophageal Adenocarcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma Primary: To compare MK-2870 to TPC with respect to OS Secondary: 1) To compare MK-2870 to TPC with respect to PFS per RECIST 1.1 as assessed by BICR 2) To compare MK-2870 to TPC with respect to ORR per RECIST 1.1 as assessed by BICR 3) To evaluate DOR per RECIST 1.1 as assessed by BICR in participants who demonstrate confirmed CR or PR during or after treatment with MK-2870 and TPC 4) To evaluate the safety and tolerability of MK-2870 Study Information